Table 3 Comparison of laboratory investigations in patients with COPD and AATD (with and without augmentation therapy). For all laboratory parameters, lsmean, diff-lsmean and CL95% and p-value from GLM are reported if not otherwise stated
From: Cardiovascular risk in patients with alpha-1-antitrypsin deficiency
Item | Total a (n = 2645) | 1 AATD + T (n = 110) | 2 AATD-T (n = 29) | 3 COPD (n = 2506) | Diff. between means (CI 95%) p-value |
|---|---|---|---|---|---|
Creatinine serum [mg/dl] | 0.89 (0.88–0.90) | 0.86 (0.81–0.91) | 0.75 (0.66–0.85) | 0.89 (0.88–0.89) | 1–2: 0.11 (−0.001 0.22) 0.053 1–3: −0.029 (−0.08 0.20) 0.243 2–3: −0.14 (−0.24–0.04) < .01 |
Uric acid [mg/dl] | 5.95 (5.88–6.01) | 5.5 (5.2–5.8) | 5.2 (4.6–5.9) | 5.9 (5.9–6.0) | 1–2: 0.23 (−0.46 0.94): 0.509 1–3: −0.51 (−0.83–0.18) 0.002 2–3: −0.75 (−1.38–0.11) 0.021 |
alpha-1-antitrypsin [mg/dl] | 142 (141–143) | 113 (107–119) | 39 (28–51) | 144 (143–146) | 1–2: 73.49 (60.46 86.51) < .0001 1–3: −31.94 (−38.07–25.82) < .0001 2–3: −105.43 (−117.05–93.81) < .0001 |
Triglyceride [mg/dl] | 142 (138–146) | 94 (73–116) | 135 (93–178) | 144 (140–149) | 1–2: −41.02 (−88.55 6.51) 0.091 1–3: −50.56 (−72.35–28.76) < .0001 2–3: −9.53 (−52.24 33.17) 0.662 |
Cholesterol [mg/dl] | 216 (215–217) | 217 (209–225) | 245 (229–261) | 216 (214–218) | 1–2: −27.91 (−46.38–9.44) 0.003 1–3: 1.27 (−7.17 9.71) 0.767 2–3: 29.18 (12.58 45.79) < .001 |
HDL Choles-terol [mg/dl] | 65 (64–66) | 71 (67–76) | 75 (66–83) | 64 (64–65) | 1–2: −3.27 (−12.62 6.08) 0.491 1–3: 7.01 (2.69 11.32) 0.002 2–3: 10.27 (1.89 18.66) 0.016 |
LDL Choles-terol [mg/dl] | 128 (127–130) | 127 (120–135) | 144 (130–159) | 128 (126–129) | 1–2: −17.15 (−33.70–0.60) 0.042 1–3: −0.57 (−8.21 7.07) 0.884 2–3: 16.58 (1.74 31.41) 0.029 |
HBA1c [mmol/mol] | 41.2 (40.8–41.5) | 37.1 (35.6–38.6) | 37.1 (34.2–39.9) | 41.4 (41.1–41.7) | 1–2: 0.01 (−3.25 3.28) 0.994 1–3: −4.29 (−5.84–2.74) < .0001 2–3: −4.30 (−7.21–1.39) 0.004 |